Charles McDermott

Charles McDermott

Director/Board Member at EQUILLIUM, INC.

Net worth: 76 157 $ as of 30/06/2026

54 year
Health Technology
Consumer Services
Commercial Services

Profile

Charles McDermott is President, Chief Executive Officer & Director at Primmune Therapeutics, Inc. since 2019.
Mr. McDermott is Chairman at Anavo Therapeutics BV.
Mr. McDermott is Independent Director at Equillium, Inc. since 2018.
Mr. McDermott is Managing Member at McDermott Consulting since 2018.
Formerly, Mr. McDermott was Director, VP-Business Development & Eye Care at Allergan, Inc. from 2005 to 2013.
Mr. McDermott was President, Director & Chief Business Officer at Impact Biomedicines, Inc. from 2017 to 2018.
Mr. McDermott was Research Scientist at Agouron Pharmaceuticals LLC.
Mr. McDermott was Principal at deCODE genetics, Inc. from 2001 to 2005.
Mr. McDermott was President & Chief Business Officer at Kala Bio, Inc. from 2014 to 2017.
Education includes graduate studies at the University of California, Santa Barbara, undergraduate studies at the University of California, Santa Cruz, and an MBA from the University of San Diego.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
28/05/2026 23,799 ( 0.04% ) 76 157 $ 30/06/2026

Charles McDermott active positions

CompaniesPositionStart
EQUILLIUM, INC. Director/Board Member 01/09/2018
Chief Executive Officer 01/03/2019
Chairman -
Corporate Officer/Principal 01/09/2018

Former positions of Charles McDermott

CompaniesPositionEnd
President 01/05/2018
KALA BIO, INC. President 07/08/2017
ALLERGAN, INC. Director/Board Member 01/05/2013
Corporate Officer/Principal 01/03/2005
Corporate Officer/Principal -
See the detail of Charles McDermott's experience

Training of Charles McDermott

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

60

1st degree connections

12

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies12

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Consumer Services

Commercial Services

Health Technology

Commercial Services

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Charles McDermott